Education

The Amp Bioresearch team goes over some basics on biotech companies and guidelines for understanding and investing in this space. Jumpstart your due diligence with our full database of upcoming catalyst events including which may be biggest movers (30-day free trial risk free): https://www.bpiq.com/ Presentation Outlines 01 - Clinical 02 - Regulatory 03 - Commercial 04 - Financial 05 - Risks ITCI, AMRN, AIMT, ZGNX, BHVN, ARQL, ACST, AXSM, EPZM, HRTX, FGEN, GBT

In this video we go over clinical trials and how they relate to investing in these clinical stage biotech / biopharma companies. Manny Vacchiano with the BiopharmIQ team goes over: - Overview of clinical trial path - Variations and nuances - Reporting out data - Risk Discover 100's of upcoming catalyst events on our biopharma research platform (free 30 day trial no cc required) : https://www.bpiq.com/ Catalyst events, biotech investing, stocks, due diligence, FDA, catalyst ca

In this video we go over how to find and analyze biopharma stock catalyst events. Manny Vacchiano with the BiopharmIQ team goes over: - Identifying catalyst events - Finding data & information - Analyzing events and info Discover 100's of upcoming catalyst events on our biopharma research platform (free 30 day trial no cc required) : https://www.bpiq.com/ Catalyst events, biotech investing, stocks, due diligence, FDA, catalyst calendar, biopharm, biopharma, catalyst, biotech,

The team at Amp Bioresearch walks you through an initial look at a very basic starting point for biotech stock due diligence. Follow along as we uncover: - Company Discovery - Catalyst Analysis - Investment Thesis - An Example Check out the tools used in this video: https://www.bpiq.com/

This Amp educational QuickE walks through the 3 key risks that are related to an individual small or mid-cap biopharma company, that drive the share price of these companies. Every smid-cap biopharma investor should understand these risks as they devise their investment strategy. Find upcoming catalysts and read actionable DD: https://www.ampbioresearch.com/ Join our Biotech Investing group chat: https://www.discord.gg/K5qt7mE [This is not investment advice.]

This Amp educational QuickE walks through the 3 key risks that are related to an individual small or mid-cap biopharma company, that drive the share price of these companies. Every smid-cap biopharma investor should understand these risks as they devise their investment strategy. Find upcoming catalysts and read read actionable DD: https://www.ampbioresearch.com/ Join our Biotech Investing group chat: https://www.discord.gg/K5qt7mE [This is not investment advice.]

This education video is part of our AmpBioResearch.com intermediate biopharma investor educational program. It discusses a very important topic for anyone who invests in small and mid-cap biopharma companies: near-term dilution and the related topic, follow-on offerings. How can you tell if a dilution event that will likely decrease a stock price, is near? What is a good vs. bad follow-on offering? And related questions for biopharma invenstors.

Be "in the know" in the pending AMRN ANDA litigation alongside experienced PhD biotech patent attorney, Manny Vacchiano. Know when impactful events will occur; and understand their significance before, during and after they unfold. Subscribe today: https://bit.ly/2MHUdxZ

Experienced PhD biotech patent attorney and biopharma investor, Manny Vacchiano, discusses some key points and events in the appeal of the district court obviousness ruling of the AMRN ANDA litigation, and discusses the #1 misconception of investors with respect to the asserted patents.

In this video we go over what biotech / biopharma stock catalyst events are and how they give investors opportunity. Manny Vacchiano with the BiopharmIQ team goes over: - Clinical trial events - Revenue/sales report outs - Corporate events - Legal actions/events Discover 100's of upcoming catalyst events on our biopharma research platform (free 30 day trial no cc required) : https://www.bpiq.com/ Catalyst events, biotech investing, stocks, due diligence, FDA, catalyst calenda